The Efficacy and Safety of Bevacizumab/Irinotecan/Temozolomide (BIT) for Relapsed/Refractory Neuroblastoma: The UK Children's Cancer and Leukaemia Group Experience
The promising efficacy and tolerability of BIT reported by the BEACON trial are reproduced in real-world data with a larger cohort. Further randomised studies are needed to separately identify optimal treatment strategies for relapsed and refractory disease.
Authors
- Ramya Ramanujachar
- Yasmeen Alomari
- Juliet C. Gray (ORCID: https://orcid.org/0000-0002-5652-4722)
- Thomas J. Jackson (ORCID: https://orcid.org/0000-0003-1669-6666)
- Upeka Senanayake (ORCID: https://orcid.org/0000-0003-2130-7709)
- David King (ORCID: https://orcid.org/0000-0002-2735-2976)
- Sucheta Vaidya (ORCID: https://orcid.org/0000-0003-2980-9316)
- Blanche Lumb
- Gerard Millen (ORCID: https://orcid.org/0000-0003-1446-3228)
- Kathleen Duffin (ORCID: https://orcid.org/0000-0003-0039-8525)
- Menna Shamma
- Ayesha Fathani
- Shaimaa Sahmoud
- Sally George
- Paola Angelini (ORCID: https://orcid.org/0000-0002-0729-3104)
- Irum Memon
- Andrei Pobischan
- Lynley V. Marshall
- Rhian Thomas
- Monzir Ahmed
- Victoria Howard
Institutions
- Boston Children's Hospital (US)
- Royal Marsden NHS Foundation Trust (GB)
- Institute of Cancer Research (GB)
- University of Liverpool (GB)
- University of Cambridge (GB)
- Leeds Teaching Hospitals NHS Trust (GB)
- Great Ormond Street Hospital (GB)
- Royal Hospital for Children (GB)
- Cambridge Hospital (US)
- Royal Edinburgh Hospital (GB)
- Bridge University (SS)
- Birmingham Children's Hospital (GB)
- Southampton Children's Hospital (GB)
- Institute of Child Health (IN)
- Great North Children's Hospital (GB)
- Alder Hey Children's Hospital (GB)
- Sheffield Children's Hospital (GB)
- University College London (GB)
Publication Details
- Journal
- Pediatric Blood & Cancer
- Published
- 2026-03-16
- DOI
- https://doi.org/10.1002/1545-5017.70226
- Primary Topic
- Neuroblastoma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00